56% of patients had RET mutations. PFS was prolonged with vandetanib in patients with/without prior TKI treatment and with sporadic forms of MTC, including those with any RET mutation and those with RETM918T; efficacy was observed in patients with hereditary MTC and RET mutations. This evidence concerns the gene RET and medullary thyroid gland carcinoma.